Pfizer Inc. and BioNTech SE agreed to their third joint messenger RNA project, an experimental shingles vaccine, expanding once more the collaboration that led to their successful shot for Covid-19.
The partners expect to start human trials of the new vaccine in the second half of this year, they said in a statement. Pfizer will pay BioNTech $225 million up-front to use its mRNA technology, including $75 million in cash and an equity investment of $150 million.
